VahatiCor announced that it has closed a $23 million Series B financing round to accelerate the clinical and engineering development of its A-FLUX Reducer System, a device intended to improve myocardial perfusion for patients suffering from Coronary Microvascular Dysfunction. The round was led by S3 Ventures with participation from Intuitive Ventures and a strategic investor. The new capital will support SERRA-I early feasibility study enrollment, continued engineering work, preparation for further clinical studies, and planning for pivotal trials and regulatory engagement.
The company, based in Santa Clara, is focused on transforming care for the millions of individuals affected by Coronary Microvascular Dysfunction. CMD is a prevalent but often overlooked condition that causes angina, chest tightness, pressure, and discomfort despite the absence of blockages in large coronary arteries. In the United States alone, between 3 and 4 million people show symptoms of myocardial ischemia without obstructive Coronary Artery Disease. Research indicates CMD disproportionately affects women and carries a heightened risk of major adverse cardiovascular events. Current medical therapies have limited success, leaving more than half of patients with persistent symptoms and no treatment options capable of improving coronary flow reserve. CMD also places considerable strain on the healthcare system, with frequent hospitalizations and diagnostic testing that often match or exceed the needs of patients with obstructive CAD.
VahatiCor’s A-FLUX Reducer System functions by creating a controlled narrowing of the coronary sinus to enhance and redistribute oxygenated blood flow to the myocardium. The repositionable, self-expanding device is designed to improve perfusion and reduce angina symptoms for patients whose conditions have not been addressed by existing therapies.
The company noted rapid enrollment progress within its SERRA-I early feasibility study, which will include 30 patients across six clinical sites. The trial is designed to evaluate both safety and effectiveness of the A-FLUX Reducer System in patients experiencing persistent symptomatic CMD.
VahatiCor is a portfolio company of T45 Labs and focuses on developing new therapeutic pathways for CMD patients who have long lacked effective treatment options. S3 Ventures and Intuitive Ventures each bring significant healthcare and technology investment expertise to the company as it prepares for broader clinical development and potential future commercialization.
KEY QUOTES:
“Securing this financing round from this esteemed group of investors is a significant validation of our therapy value proposition and the quality of our team. VahatiCor can continue executing the critical next phase of our strategy to advance A-FLUX® through clinical studies and fulfill our mission of making this breakthrough therapy available to the millions suffering from Coronary Microvascular Dysfunction. We are proud and excited to work on an interventional treatment that aims to provide meaningful clinical benefit and symptom relief and improve the quality of life for millions of patients worldwide.”
Marwan Berrada-Sounni, Co-Founder of VahatiCor
“We believe VahatiCor’s A-FLUX Reducer System® represents a significant breakthrough for an enormous and underserved patient population in need of a true solution. The company’s unique approach leveraging a repositionable, self-expanding device provides a meaningful advantage in procedural safety and efficacy, positioning them to become the clear leader in coronary sinus therapy.”
Brian R. Smith, Managing Director, S3 Ventures
“The high symptom burden of recurring angina, reduced exercise capacity, diminished quality of life, and psychological distress caused by delayed diagnosis demands more clinical awareness and effective therapies that prioritize the patient experience. VahatiCor’s A-FLUX is exactly the type of life-changing, patient-centered innovation we aim to support. We are confident in the company’s ability to follow the clinical pathway necessary to bring this long-awaited option to market.”
Terri Burke, Senior Partner, Intuitive Ventures
